Liver Cirrhosis
Conditions
Brief summary
The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.
Detailed description
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
Interventions
DRUGADSCs
autologous ADSCs
Sponsors
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Liver cirrhosis investigators with age 20 to 80 years (both inclusive). 2. Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis) 3. Investigators without rare disorder 4. Coagulation normalities 5. Investigators without autoimmune disorder 6. Investigators without Acquired Immune Deficiency Syndrome 7. Investigators without cancer 8. Investigators BMI \> 15
Exclusion criteria
1. Pregnant women 2. Investigators with acute stroke in one month and unconsciousness 3. Investigators with acute myocardial infarction or acute heart failure 4. Investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher 5. Investigators with acute respiratory failure or pneumonia 6. Kidney Failure: BUN \> 50 7. Anemia: Hematocrit \< 25 8. Investigators diagnosed with liver cancer or liver metastatic carcinoma 9. Investigators with liver abscess 10. Investigators with acute Hepatitis 11. Investigators with acute infective 12. Liver cirrhosis patients with HBV or HCV 13. Investigators diagnosed with carcinoma and receiving treatment 14. Investigators with Schizophrenia or melancholia 15. Investigators received serious surgical operations in 3 months 16. Investigators unable to control hypertension (SBP \> 180 mmHg, DBP \> 110 mmHg) or diabetes (AC sugar \> 200 mg/dl) 17. Others can't fit into the trial evaluate by investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MELD | 1-6 month | MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula:MELD = 3.78\[Ln serum bilirubin (mg/dL)\] + 11.2\[Ln INR\] + 9.57\[Ln serum creatinine (mg/dL)\] + 6.43. |
Countries
Taiwan
Outcome results
None listed